Amendments to the claims:

1. (Currently Amended) A composition for use in treating epithelial lesions formed of a combination of ingredients comprising:

8-hydroxyquinoline in an amount of at least five percent of the composition by weight;

an escharotic chelatable metal agent bonded to said 8-hydroxyquinoline, ~~including~~ the escharotic chelatable metal agent comprising a metal having an oxidation state of +2 present in a concentration of at least five percent by weight of the composition and less than an amount that produces an eschar in healthy mammalian tissues; and

a carrier,

the composition having a capacity for treating at least one type of lesion selected from the group consisting of venereal warts, male veruoca warts, lesions produced by the human papilloma virus, basal cell carcinoma, solar keratosis, Kaposi's sarcoma, eye cancer, sarcoids, sarcoma, malignant melanoma, rectal adenoma, histocytoma, sebaceous adenoma, lung cancer, breast cancer, and colon cancer.

2. (Currently Amended) The composition as set forth in claim 1, wherein the ~~including a ratio of~~ 8-hydroxyquinoline ~~to said~~ and the escharotic chelatable metal agent are present in a ratio (8-hydroxyquinoline:escharotic chelatable metal agent) ranging from 1:1 to 1:3 by weight.

3. (Previously Amended) The composition as set forth in claim 2 wherein said ratio is about 1:2.

4. (Previously Amended) The composition as set forth in claim 1 wherein said escharotic chelatable metal agent comprises zinc.

5. (Original) The composition as set forth in claim 1 wherein said escharotic chelatable metal agent comprises zinc chloride in an amount up to forty percent by weight of said composition by weight.

6. (Original) The composition as set forth in claim 1 wherein said escharotic chelatable metal agent comprises zinc chloride in an amount ranging up to twenty percent.

7. (Currently Amended) The composition as set forth in claim 1 in combination with necrotic tissue from a lesion ~~lesions~~ of said group produced by the action of said composition upon the lesion~~said necrotic tissue~~.

8. Cancelled.

9. Cancelled.

10. Cancelled.

11. Cancelled.

12. Cancelled.

13. Cancelled.

14. (Original) The composition as set forth in claim 1, wherein said carrier is a gel base.

15. (Original) The composition as set forth in claim 14 wherein said gel base is a polyoxyalkylene ether derivative of propylene glycol.

16. (Original)The composition as set forth in claim 1 wherein said carrier contains a penetrant.

17. (Original) The composition as set forth in claim 1 wherein said penetrant is lecithin.

18. (Original) The composition as set forth in claim 1 wherein said penetrant is dimethyl sulfoxide.

19. (Original) The composition as set forth in claim 1 wherein said carrier contains an antioxidant.

20. (Original) The composition as set forth in claim 19 wherein said antioxidant is selected from the group consisting of nordihydroguiaretic acid, nordihydroguiaretic acid derivatives, and functional homologues of nordihydroguiaretic acid.

21. (Original) The composition as set forth in claim 19 wherein said antioxidant is selected from a group consisting of ascorbic acid, ascorbic acid derivatives, and functional homologues of ascorbic acid.

22. Canceled

23. Canceled

24. Canceled

25. Canceled

26. Canceled

27. Canceled

28. Canceled

29. Canceled

30. Canceled

31. Canceled

32. Canceled

33. Canceled

34. (Original) The composition as set forth in claim 1 wherein said carrier consists essentially of an antioxidant.

35. (Original) The composition as set forth in claim 34 wherein said antioxidant consists essentially of an ascorbate.

36. (Original) The composition as set forth in claim 34 wherein the antioxidant consists essentially of nordihydroguiaretic acid.

37. (Original) The composition as set forth in claim 1 wherein the metal comprises a heavy metal.

38 Canceled.

39. (New) A composition for use in treating epithelial lesions formed of a combination of ingredients comprising:

8-hydroxyquinoline in an amount of at least five percent of the composition by weight;

zinc bonded to said 8-hydroxyquinoline, the zinc being present in a concentration of at least five percent by weight of the composition and less than an amount that produces an eschar in healthy mammalian tissues; and

a carrier.

40. (New) The composition of claim 39, the 8-hydroxyquinoline and the zinc being present in effective amounts for treating at least one type of lesion selected from the group consisting of venereal warts, male veruoca warts, lesions produced by the human papilloma virus, basal cell carcinoma, solar keratosis, Kaposi's sarcoma, eye cancer, sarcoids, sarcoma, malignant melanoma, rectal adenoma, histocytoma, sebaceous adenoma, lung cancer, breast cancer, and colon cancer.

41. (New) The composition as set forth in claim 39, wherein the 8-hydroxyquinoline and the zinc are present in a ratio (8-hydroxyquinoline:zinc) ranging from 1:1 to 1:3 by weight.

42. (New) The composition as set forth in claim 41, wherein the ratio is about 1:2.

43. (New) The composition as set forth in claim 41, wherein the 8-hydrozyquinoline is present in an amount of in an amount ranging up to twenty percent.

44. (New) The composition as set forth in claim 39 in combination with necrotic tissue from a lesion of said group produced by the action of the composition upon the lesion.

45. (New) The composition as set forth in claim 39, wherein the carrier is a gel base.

46. (New) The composition as set forth in claim 45, wherein the gel base is a polyoxyalkylene ether derivative of propylene glycol.

47. (New)The composition as set forth in claim 39, wherein the carrier contains a penetrant.

48. (New) The composition as set forth in claim 39, wherein the penetrant is lecithin.

49. (New) The composition as set forth in claim 39, wherein the penetrant is dimethyl sulfoxide.

50. (New) The composition as set forth in claim 39, wherein the carrier contains an antioxidant.

51. (New) The composition as set forth in claim 50, wherein the antioxidant is selected from the group consisting of nordihydroguiaretic acid, nordihydroguiaretic acid derivatives, and functional homologues of nordihydroguiaretic acid.

52. (New) The composition as set forth in claim 50, wherein the antioxidant is selected from a group consisting of ascorbic acid, ascorbic acid derivatives, and functional homologues of ascorbic acid.